Press release
Chronic Inflammation Treatment Market to Grow at Significant CAGR through 2031, Driven by Rising Prevalence of Chronic Diseases and Emerging Targeted Therapies | DataM Intelligence
Chronic Inflammation Treatment Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/chronic-inflammation-treatment-market?jd
United States Key Industry Developments
☑️ January 2026: Halia Therapeutics advanced its NLRP3 inhibitor program with positive Phase 1 data, positioning it as a potential breakthrough for broad chronic inflammation applications.
☑️ January 2026: Amgen expanded access programs for its anti-inflammatory portfolio, including Enbrel biosimilars, amid growing demand for arthritis and cardiovascular inflammation management.
☑️ December 2025: NodThera reported encouraging interim results from its NLRP3-targeted candidate in inflammatory diseases, attracting increased investor and partnership interest.
☑️ December 2025: Pfizer Inc. highlighted strong real-world evidence for its NSAIDs and statin combinations in chronic inflammation control, reinforcing market leadership.
Japan Key Industry Developments
☑️ January 2026: Takeda Pharmaceutical Company Limited accelerated rollout of its advanced anti-inflammatory agents, supported by updated national reimbursement policies for chronic disease management.
☑️ January 2026: Local and global players showcased next-generation biologics and NLRP3 inhibitors at major immunology conferences in Tokyo, focusing on diabetes and arthritis applications.
☑️ December 2025: Growing adoption of combination therapies including metformin and NSAIDs in outpatient settings, driven by rising diabetes and COPD prevalence.
Key Mergers and Acquisitions
✦ Eli Lilly and Company announced a definitive agreement to acquire Ventyx Biosciences for approximately US$ 1.2 billion (announced January 7, 2026), strengthening its oral immunology pipeline with NLRP3 inflammasome inhibitors applicable to chronic inflammatory conditions.
✦ AbbVie entered advanced discussions to potentially acquire Revolution Medicines for over US$ 20 billion (reports January 7-8, 2026), targeting RAS pathway assets with potential crossover benefits in inflammatory signaling pathways.
✦ Amgen continued its immunology expansion strategy with integration of recent acquisitions and bolt-on deals in chronic inflammation therapeutics in early 2026.
Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=chronic-inflammation-treatment-market
Market Segmentation Analysis
By Type: Granulomatous Inflammation (including Infectious and Foreign Body Granuloma) and Nonspecific Proliferative lead segments.
By Medications: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) dominate; followed by Statins, Corticosteroids, Metformin, Herbal Supplements, and Others.
By Chronic Inflammation Disease Type: Diabetes, Cardiovascular Diseases, Arthritis and Joint Diseases, COPD, Allergies, and Others.
By Distribution Channel: Hospital Pharmacy leads; followed by Retail Pharmacy and Online Pharmacy.
Regional Insights
North America commands the largest market share in the global Chronic Inflammation Treatment market, supported by high prevalence of chronic diseases, advanced healthcare systems, widespread use of NSAIDs, statins, and biologics, strong reimbursement for anti-inflammatory therapies, and the presence of leading pharmaceutical innovators driving clinical development and market access. Asia-Pacific remains the fastest-growing region, fueled by rapidly rising incidence of diabetes, cardiovascular diseases, and arthritis, increasing healthcare expenditure, expanding access to affordable generics and biologics, growing adoption of online pharmacies, and aggressive investments by global and regional players in emerging markets.
Growth Drivers
✦ Growing global burden of chronic inflammatory diseases including diabetes, arthritis, and CVD
✦ Strong demand for NSAIDs, statins, and corticosteroids in standard care
✦ Emerging targeted therapies like NLRP3 inhibitors showing promise in clinical pipelines
✦ Increasing use of herbal supplements and combination treatments
✦ Expanding distribution through online and retail channels in developing regions
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chronic-inflammation-treatment-market?jd
Key Players
The market includes leading companies such as Pfizer Inc., NodThera, Abcentra, Evommune, Inc., Sterna biologicals, Halia Therapeutics, Inc., Amgen Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, Annexon, Inc., and others.
Key Highlights (Top 5 Key Players)
✦ Pfizer Inc. - Leading with broad NSAID and statin portfolio for chronic inflammation management.
✦ Amgen Inc. - Strong in biologics and biosimilars for arthritis and inflammatory conditions.
✦ Halia Therapeutics - Advancing innovative NLRP3 inhibitors for broad anti-inflammatory applications.
✦ NodThera - Pioneering targeted inflammasome therapies in clinical development.
✦ Takeda Pharmaceutical Company Limited - Dominating in Asia-Pacific with comprehensive chronic disease treatments.
Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd
Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Inflammation Treatment Market to Grow at Significant CAGR through 2031, Driven by Rising Prevalence of Chronic Diseases and Emerging Targeted Therapies | DataM Intelligence here
News-ID: 4341568 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Physician Dispensed Cosmeceuticals Market to Reach US$ 69.84 Billion by 2033 at …
The physician dispensed cosmeceuticals market reached US$ 36.55 billion in 2024 and is projected to reach US$ 69.84 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025-2033, according to the DataM Intelligence report. Market growth is primarily driven by increasing consumer preference for clinically proven, dermatologist-recommended skincare products that address concerns such as aging, acne, hyperpigmentation, and sensitive skin. Rising awareness of skin health, coupled…
Point-of-Care Ultrasound Market to Reach US$ 4.60 Billion by 2033 at 8.8% CAGR; …
The point-of-care ultrasound (POCUS) market reached US$ 1.99 billion in 2023, increased to US$ 2.16 billion in 2024, and is projected to reach US$ 4.60 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033. Market expansion is driven by the growing need for rapid, accurate, and bedside diagnostic imaging across emergency care, critical care, anesthesiology, cardiology, and primary care settings. The shift toward decentralized healthcare…
Procurement as a Service Market to Reach US$ 16.74 Billion by 2033 at 10.4% CAGR …
The global Procurement as a Service (PaaS) market reached US$ 6.30 billion in 2023, increased to US$ 6.87 billion in 2024, and is expected to reach US$ 16.74 billion by 2033, growing at a CAGR of 10.4% during the forecast period 2025-2033. Market growth is driven by rising demand from manufacturing, automotive, electronics, and healthcare industries for scalable, cost-efficient procurement solutions. Organizations are increasingly adopting PaaS to streamline sourcing, supplier…
Precision Potentiometers Market Set for Strong Growth to USD 2.30 Billion by 203 …
The Global Precision Potentiometers Market reached USD 1.40 billion in 2023 and is expected to reach USD 2.30 billion by 2031, growing with a CAGR of 6.3% during the forecast period 2024-2031.
Market growth is driven by rising demand for high-accuracy sensing in electronics, automotive electronics, and industrial automation. Advancements in miniaturization, integration with IoT devices, expanding applications in aerospace and medical devices, and growing emphasis on precision instrumentation are further…
More Releases for Inflammation
United States Chronic Inflammation Treatment Market 2025 | Granulomatous inflamm …
Leander, Texas and Tokyo, Japan - Nov.24.2025
As per DataM intelligence research report" The global chronic inflammation treatment market is expected to reach at a Significant CAGR during the forecast period 2024-2031." Advances in biologics and rising autoimmune conditions are shaping the chronic inflammation treatment landscape.
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/chronic-inflammation-treatment-market?Prasad
United States: Recent Industry Developments
✅ In November 2025, Pfizer launched a next-generation chronic inflammation therapy…
Inflammation Test Kit Market Trends, Demand, and Future Outlook
The global inflammation test kit market is projected to reach a value of approximately $2.5 billion in 2024. Anticipating robust growth, it is expected to expand significantly, reaching around $4.6 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 6.5% during the 2025-2034 forecast period.
Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of…
Global Inflammation Supplement Market - Natural Solutions for Chronic Inflammati …
The Global Inflammation Supplement Market reached at a CAGR during the forecast period 2024-2031.
Inflammation Supplement Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients…
Shaping the Ocular Inflammation Treatment Market in 2025: Advancements In Ocular …
How Big Is the Ocular Inflammation Treatment Market Expected to Be, and What Will Its Growth Rate Be?
The market size for the treatment of ocular inflammation has significantly expanded in the past few years. The market will witness growth from $9.38 billion in 2024 to $9.97 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. The progressive growth within the historical timeframe can be credited to factors…
Green Coffee: Improved Brain Function and Reduced Inflammation
Green coffee is coffee that has not been roasted. The coffee beans are left in their natural state, which means they are not exposed to the high temperatures that occur during the roasting process. This results in a coffee that has a lower acidity level and a more subtle flavor. Many people believe that green coffee has a number of health benefits, including weight loss, improved brain function, and reduced…
Global Clinical Trials Cardiovascular Inflammation Review, H1, 2017
"The Report Cardiovascular Inflammation Global Clinical Trials Review, H1, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
GlobalData's clinical trial report, Cardiovascular Inflammation Global Clinical Trials Review, H1, 2017" provides an overview of Cardiovascular Inflammation clinical trials scenario. This report provides top line data relating to the clinical trials on Cardiovascular Inflammation. Report includes an overview of trial numbers and…
